Close Menu

NEW YORK (GenomeWeb News) – BioFocus and DiscoveRx have signed a co-marketing pact that allows BioFocus to offer screening services using DiscoveRx's assay technologies, BioFocus said today.

Under the agreement, BioFocus, based in Saffron Walden, UK, will offer to its customers DiscoverX's PathHunter beta-arrestin GPCR assays, HitHunter cAMP assays, and associated cell lines.

"The addition of the DiscoveRx GPCR product portfolio to BioFocus will enhance our assay development and screening platform,” Chris Newton, senior vice president at BioFocus, said in a statement.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.